No Data
In-Depth Examination Of 10 Analyst Recommendations For Compass
In the preceding three months, 10 analysts have released ratings for Compass (NYSE:COMP), presenting a wide array of perspectives from bullish to bearish.Summarizing their recent assessments, the tabl
Express News | HC Wainwright & Co. Reiterates Buy on Compass Therapeutics, Maintains $10 Price Target
Compass Is Maintained at Neutral by UBS
Compass Is Maintained at Neutral by UBS
Express News | UBS Maintains Neutral on Compass, Raises Price Target to $4
Compass Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 -7.83% UBS $3.5 → $4 Maintains Neutral 05/09/2024 15.21% Needham → $5 Reiterates Buy → Buy 03/0
Buy Rating Affirmed for Compass Therapeutics on Strong Financials and Promising Clinical Trials